Saturday 17 October 2026
Export LNTH’s income statement to Excel — free account
Lantheus Holdings, Inc.
LNTH Healthcare Drug Manufacturers Specialty & Generic
Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024. In the quarter to June 2026, revenue grew 2.68%, EPS was flat, free cash flow grew 13.6% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.
99.70
0.29
−0.29%
Follow LNTH
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
19.35 | 19.79 | 13.20 | 123.59 | 0.00 | 0.00 | 25.32 | 14.76 | 6.38 | 10.41 |
Piotroski F-Score |
5 | 5 | 7 | 7 | 5 | 3 | 4 | 6 | 6 | 6 |
P/S ratio |
2.91 | 4.04 | 3.32 | 3.71 | 4.59 | 2.15 | 2.30 | 1.74 | 2.36 | 0.94 |
Altman Z-Score |
4.25 | 6.67 | 5.32 | 3.38 | 3.03 | 1.51 | 2.77 | 2.09 | 2.13 | 0.86 |
P/FCF ratio |
12.69 | 12.82 | 12.08 | 13.08 | 33.85 | 186.20 | 13.71 | 14.23 | 20.35 | 5.37 |
Altman Z″-Score (non-manufacturers) |
4.61 | 7.16 | 6.34 | 2.38 | 1.02 | 1.71 | 1.90 | 2.07 | 0.93 | (1.34) |
Beneish M-Score |
(2.23) | (2.97) | (2.08) | (2.79) | (2.83) | (1.68) | (3.02) | (2.62) | (1.15) | (2.87) |
P/Operating CF |
49.81 | 39.25 | 38.36 | 32.94 | 140.38 | 1,283.42 | 35.67 | 34.57 | 59.82 | 22.19 |
P/B ratio |
4.12 | 5.69 | 5.28 | 7.76 | 4.20 | 1.42 | 6.98 | 8.43 | 33.61 | 0.00 |
Price to Tangible BV |
35.23 | 7.16 | 7.15 | 49.10 | 35.62 | 9.18 | 7.45 | 12.96 | 0.00 | 0.00 |
EV/Sales |
3.05 | 3.81 | 3.21 | 3.86 | 4.76 | 2.56 | 2.59 | 2.19 | 2.94 | 1.69 |
EV/EBITDA |
12.20 | 11.11 | 9.69 | 42.32 | 0.00 | 42.17 | 13.64 | 9.43 | 13.45 | 6.68 |
EV/Operating CF |
12.05 | 10.73 | 13.62 | 12.82 | 37.58 | 53.00 | 11.21 | 12.28 | 17.79 | 10.28 |
EV/FCF |
13.28 | 12.10 | 11.66 | 13.62 | 35.17 | 221.58 | 15.44 | 17.86 | 25.34 | 9.66 |
Quick Ratio |
2.20 | 5.16 | 5.33 | 2.54 | 2.08 | 1.66 | 2.06 | 2.98 | 2.49 | 2.01 |
Current Ratio |
2.70 | 5.52 | 5.80 | 2.74 | 2.61 | 2.29 | 2.62 | 3.70 | 3.16 | 2.53 |
Net Debt/EBITDA |
0.55 | (0.66) | (0.35) | 1.67 | (4.27) | 6.73 | 1.53 | 1.92 | 2.65 | 2.97 |
Debt/Assets |
25.56% | 28.59% | 34.07% | 42.24% | 20.23% | 25.11% | 47.81% | 60.58% | 69.85% | 108.68% |
Debt/Equity |
0.52 | 0.52 | 0.69 | 1.25 | 0.38 | 0.42 | 1.69 | 3.75 | 11.51 | (2.61) |
Asset Turnover |
0.73 | 0.84 | 0.87 | 0.86 | 0.49 | 0.53 | 0.82 | 0.83 | 1.04 | 1.21 |
Operating CF/Net income |
1.67 | 1.74 | 0.93 | 10.04 | (0.76) | (1.22) | 2.54 | 1.51 | 0.44 | 1.85 |
Capex/Depreciation |
(0.48) | (0.90) | 0.80 | (0.34) | 0.09 | (0.50) | (1.54) | (1.26) | (0.79) | 0.16 |
Interest Coverage |
15.74 | 23.23 | 18.21 | 5.04 | (7.85) | (0.44) | 3.79 | 3.71 | 2.82 | 2.13 |
| 21.45% | 32.82% | 51.73% | 6.16% | (14.57%) | (4.29%) | 34.12% | 85.94% | (296.51%) | (18.34%) | |
| 11.10% | 17.21% | 21.98% | 2.57% | (8.22%) | (2.11%) | 7.49% | 9.84% | 38.57% | 10.74% | |
ROIC |
14.94% | 38.52% | 34.28% | 3.84% | (7.03%) | (0.40%) | 14.97% | 17.99% | 15.06% | 29.37% |
Return on Tangible Assets |
31.98% | 24.74% | 31.25% | 5.08% | (27.20%) | (6.02%) | 14.18% | 16.17% | 63.57% | 16.61% |
Average Days of Receivables |
88.56 | 78.39 | 80.04 | 83.30 | 76.69 | 58.07 | 45.74 | 46.51 | 44.34 | 44.52 |
Research and Development Expense of Revenue |
11.50% | 10.96% | 5.99% | 33.33% | 10.58% | 9.66% | 5.76% | 4.97% | 5.47% | 4.04% |
Selling, General and Administrative Expense of Revenue |
29.44% | 24.23% | 20.61% | 25.01% | 51.46% | 32.46% | 29.69% | 27.18% | 27.81% | 24.97% |
Intangible Assets out of Total Assets |
0.43 | 0.11 | 0.13 | 0.28 | 0.47 | 0.50 | 0.02 | 0.06 | 0.07 | 0.12 |
Share Based Compensation of Revenue |
5.55% | 4.98% | 3.90% | 3.13% | 3.75% | 4.15% | 3.60% | 2.54% | 1.79% | 0.84% |
Graham Net Nets |
(0.05) | 0.07 | 0.06 | (0.06) | (0.08) | (0.23) | (0.15) | (0.29) | (0.27) | (0.89) |
Graham Number |
35.35 | 39.99 | 35.85 | 7.76 | 0.00 | 0.00 | 7.32 | 6.66 | 6.80 | 0.00 |
Earnings Yield |
5.17% | 5.05% | 7.58% | 0.81% | (3.63%) | (1.70%) | 3.95% | 6.77% | 15.67% | 9.60% |
Free Cash Flow Yield |
7.88% | 7.80% | 8.28% | 7.64% | 2.95% | 0.54% | 7.29% | 7.03% | 4.91% | 18.64% |
Revenue per Share |
22.84 | 22.17 | 18.99 | 13.65 | 6.30 | 6.27 | 8.91 | 8.98 | 8.89 | 9.42 |
Operating CF per Share |
5.78 | 7.87 | 4.47 | 4.11 | 0.80 | 0.30 | 2.06 | 1.60 | 1.47 | 1.55 |
Capex per Share |
(0.53) | (0.89) | 0.75 | (0.24) | 0.05 | (0.23) | (0.57) | (0.50) | (0.44) | 0.10 |
Free Cash Flow per Share |
5.25 | 6.98 | 5.22 | 3.87 | 0.85 | 0.07 | 1.50 | 1.10 | 1.03 | 1.65 |
Cash per Share |
5.32 | 13.19 | 10.45 | 6.07 | 1.46 | 1.47 | 2.38 | 2.97 | 2.05 | 1.60 |
Shareholders Equity per Share |
16.15 | 15.72 | 11.95 | 6.53 | 6.88 | 9.50 | 2.94 | 1.86 | 0.62 | (3.32) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
16.15 | 15.72 | 11.95 | 6.53 | 6.88 | 9.50 | 2.94 | 1.86 | 0.62 | (3.32) |
Free Cash Flow |
354.05 | 482.89 | 356.54 | 265.23 | 57.60 | 3.92 | 58.32 | 42.06 | 38.47 | 52.85 |
Working Capital |
566.55 | 1,086.11 | 898.47 | 429.92 | 145.29 | 103.72 | 106.80 | 142.66 | 101.10 | 66.98 |
Capital Expenditures |
(36.09) | (61.86) | 51.28 | (16.55) | 3.68 | (12.47) | (22.06) | (19.13) | (16.31) | 3.21 |
Net Current Asset Value |
(237.64) | 434.30 | 250.56 | (196.49) | (163.55) | (171.39) | (118.41) | (173.41) | (212.72) | (251.59) |
EV/EBIT |
15.13 | 12.79 | 11.40 | 99.81 | 0.00 | 0.00 | 17.44 | 11.65 | 18.80 | 9.02 |
Capex to Sales |
0.02 | 0.04 | (0.04) | 0.02 | (0.01) | 0.04 | 0.06 | 0.06 | 0.05 | (0.01) |
Price to Operating Income |
14.45 | 13.55 | 11.81 | 95.88 | 0.00 | 0.00 | 15.48 | 9.28 | 15.10 | 5.01 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.46 | 0.39 | 0.44 | 0.40 | 0.37 | 0.21 | 0.12 | 0.14 | 0.22 | 0.21 |
Cash ROIC |
17.54% | 18.81% | 17.04% | 18.67% | 7.81% | 0.48% | 14.52% | 9.33% | 10.46% | 23.72% |
Accounts Receivable Turnover |
4.38 | 5.00 | 5.21 | 6.18 | 5.93 | 6.96 | 7.96 | 8.17 | 8.60 | 8.15 |
Accounts Payable Turnover |
15.48 | 14.41 | 19.01 | 17.09 | 12.81 | 11.50 | 9.44 | 9.51 | 9.30 | 10.72 |
Inventory Turnover |
9.04 | 8.26 | 11.80 | 10.01 | 6.70 | 6.18 | 5.55 | 5.70 | 7.74 | 9.87 |
Average Days of Payables |
26.12 | 23.12 | 25.62 | 21.24 | 31.94 | 29.62 | 39.37 | 38.90 | 37.66 | 42.13 |
Days of Inventory on Hand |
39.37 | 45.51 | 39.82 | 36.64 | 53.98 | 65.02 | 61.73 | 71.53 | 56.25 | 39.24 |
Average Receivables |
351.73 | 306.86 | 248.84 | 151.37 | 71.67 | 48.77 | 43.64 | 42.01 | 38.54 | 37.06 |
Average Payables |
38.73 | 37.87 | 30.88 | 20.68 | 18.54 | 17.45 | 18.28 | 17.71 | 18.20 | 15.30 |
Average Inventory |
66.35 | 66.03 | 49.75 | 35.30 | 35.44 | 32.46 | 31.10 | 29.55 | 21.86 | 16.63 |
Average Assets |
2,103.87 | 1,815.74 | 1,486.20 | 1,092.52 | 866.80 | 637.87 | 422.88 | 411.84 | 319.88 | 249.14 |
Average Common Equity |
1,088.90 | 951.95 | 631.52 | 455.79 | 489.32 | 314.40 | 92.80 | 47.15 | (41.61) | (145.90) |
Columns are period end dates